Guardant Health, Inc., a leader in precision oncology, announced today that Nasdaq has temporarily suspended trading of their stock. The Molecular and Clinical Genetics Panel of the U.S. Food and Drug Administration (FDA) Medical Devices Advisory Committee is set to meet today to evaluate the premarket approval (PMA) application for ShieldTM, Guardant Health’s blood test designed to screen for colorectal cancer in average-risk adults.
The FDA advisory committees play a vital role in providing independent expert advice and non-binding recommendations to the FDA on specific products, helping the agency make well-informed decisions based on scientific evidence. Founded in 2012, Guardant Health is dedicated to advancing precision oncology and promoting overall wellness. The company offers valuable insights into disease mechanisms through their advanced blood and tissue tests, as well as real-world data and AI analytics.
Guardant’s tests are designed to enhance patient outcomes at all stages of care, from early cancer detection to treatment selection for patients with advanced cancer. For more information about Guardant Health, visit guardanthealth.com and connect with the company on LinkedIn, Twitter, and Facebook.
Investor inquiries can be directed to Zarak Khurshid at investors@guardanthealth.com, while media contacts can reach out to Mike Weist at press@guardanthealth.com or +1 650-647-3643.
